These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Rajkumar SV; Witzig TE Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136 [TBL] [Abstract][Full Text] [Related]
23. [Thalidomide: new uses for an old drug]. Wu KL; Sonneveld P Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1438-41. PubMed ID: 12190008 [TBL] [Abstract][Full Text] [Related]
24. [Thalidomide for the treatment of refractory multiple myeloma]. Kakimoto T; Hattori Y; Okamoto S Rinsho Ketsueki; 2002 May; 43(5):345-8. PubMed ID: 12096483 [No Abstract] [Full Text] [Related]
25. Efficacy and safety of thalidomide in the treatment of multiple myeloma. Warzocha K; Kraj M; Pogłód R; Szpila T; Mendek-Czajkowska E; Chełstowska M; Tronina RH Acta Pol Pharm; 2008; 65(6):771-4. PubMed ID: 19172865 [No Abstract] [Full Text] [Related]
26. Mechanism of teratogenic action of thalidomide. Vaisman B Teratology; 1996 May; 53(5):283-4. PubMed ID: 8879085 [No Abstract] [Full Text] [Related]
27. Second response to lower-dose thalidomide in a patient with multiple myeloma. Lee FC Blood; 2002 Jun; 99(11):4248; author reply 4249. PubMed ID: 12043696 [No Abstract] [Full Text] [Related]
28. Successful Treatment of Recurrent Gastrointestinal Bleeding Due to Small Intestine Angiodysplasia and Multiple Myeloma with Thalidomide: Two Birds with One Stone. Hude I; Batinić J; Kinda SB; Pulanić D Turk J Haematol; 2018 Nov; 35(4):305-306. PubMed ID: 29911985 [No Abstract] [Full Text] [Related]
29. Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses. Miller MT; Strömland K Teratology; 1999 Nov; 60(5):306-21. PubMed ID: 10525208 [No Abstract] [Full Text] [Related]
31. Low-dose of thalidomide in the treatment of refractory myeloma. Pini M; Baraldi A; Pietrasanta D; Allione B; Depaoli L; Salvi F; Levis A Haematologica; 2000 Oct; 85(10):1111-2. PubMed ID: 11025615 [No Abstract] [Full Text] [Related]
32. [Bone marrow angiogenesis in multiple myeloma: new insights into the pathogenesis, and development of a new therapeutic approach]. Hattori Y; Kakimoto T Rinsho Ketsueki; 2000 May; 41(5):426-9. PubMed ID: 10879105 [No Abstract] [Full Text] [Related]
33. Complete resolution of reflex sympathetic dystrophy with thalidomide treatment. Rajkumar SV; Fonseca R; Witzig TE Arch Intern Med; 2001 Nov; 161(20):2502-3. PubMed ID: 11700165 [No Abstract] [Full Text] [Related]
34. Early changes in bone marrow morphology induced by thalidomide in refractory myeloma patients. Corso A; Lorenzi A; Zappasodi P; Invernizzi R; Vanelli L; Lazzarino M Haematologica; 2003 Aug; 88(8):958-60. PubMed ID: 12935985 [No Abstract] [Full Text] [Related]
36. [Thalidomide: (re)discovery of a not very dear old molecule]. Bressoud A; Schwab BZ Rev Med Suisse Romande; 2003 Apr; 123(4):238-40. PubMed ID: 15088555 [TBL] [Abstract][Full Text] [Related]
37. Thalidomide. A new beginning. Valorie AM Cancer Pract; 2000; 8(2):101-3. PubMed ID: 11898173 [No Abstract] [Full Text] [Related]